Patents by Inventor Vanessa L. Rada
Vanessa L. Rada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970479Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.Type: GrantFiled: October 24, 2019Date of Patent: April 30, 2024Assignees: Merck Sharp & Dohme LLC, MSD R&D (China) Co. LTD.Inventors: John J. Acton, III, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Timothy J. Henderson, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, James Mulhearn, Vanessa L. Rada, Jeffrey W. Schubert, Oleg B. Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang, Jianming Bao, Chunsing Li
-
Publication number: 20240101555Abstract: The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 14, 2021Publication date: March 28, 2024Applicant: Merck Sharp & Dohme LLCInventors: Kira A. Armacost, Maria Irina Chiriac, Danielle M. Hurzy, Jeffrey C. Kern, Jian Liu, Peter J. Manley, Philippe Nantermet, Vanessa L. Rada, Michael T. Rudd, Craig A. Stump
-
Publication number: 20230391795Abstract: The present invention is directed to macrocyclic urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: October 28, 2021Publication date: December 7, 2023Applicant: Merck Sharp & Dohme LLCInventors: Kira A. Armacost, Maria Irina Chiriac, Danielle M. Hurzy, Jeffrey C. Kern, Jian Liu, Peter J. Manley, Vanessa L. Rada, Michael T. Rudd, Craig A. Stump, Zhe Wu, Dong Xiao
-
Patent number: 11332463Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).Type: GrantFiled: April 29, 2019Date of Patent: May 17, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Brian T. Campbell, Harry R. Chobanian, James I. Fells, Deodial G. Guiadeen, Thomas J. Greshock, Kenneth J. Leavitt, Vanessa L. Rada, Ian M. Bell
-
Publication number: 20210395224Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.Type: ApplicationFiled: October 24, 2019Publication date: December 23, 2021Applicants: Merck Sharp & Dohme Corp., MSD R&D (China) Co. LTD.Inventors: John J. Acton, III, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Timothy J. Henderson, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, James Mulhearn, Vanessa L. Rada, Jeffrey W. Schubert, Oleg B. Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang, Jianming Bao, Chunsing Li
-
SUBSTITUTED 6-MEMBERED ARYL OR HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
Publication number: 20210196734Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammationType: ApplicationFiled: March 5, 2021Publication date: July 1, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada -
Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
Patent number: 11026958Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: GrantFiled: October 30, 2017Date of Patent: June 8, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, Brian T. Campbell, Thomas J. Greshock, Vanessa L. Rada -
SUBSTITUTED 6-MEMBERED ARYL OR HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
Publication number: 20210077511Abstract: present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: ApplicationFiled: October 30, 2017Publication date: March 18, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, BRIAN T. CAMPBELL, THOMAS J. GRESHOCK, VANESSA L. RADA -
Publication number: 20210070745Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).Type: ApplicationFiled: April 29, 2019Publication date: March 11, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Brian T. Campbell, Harry R. Chobanian, James I. Fells, Deodial G. Guiadeen, Thomas J. Greshock, Kenneth J. Leavitt, Vanessa L. Rada, Ian M. Bell
-
Patent number: 10870630Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: GrantFiled: October 30, 2017Date of Patent: December 22, 2020Inventors: Brendan M. Crowley, Ian M. Bell, Andrew John Harvey, William D. Shipe, Kenneth J. Leavitt, John M. Sanders, Deodial G. Guiadeen, Linda M. Suen, Thomas J. Greshock, Vanessa L. Rada
-
Publication number: 20190337910Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: ApplicationFiled: March 20, 2017Publication date: November 7, 2019Applicant: MERCK SHARP & DOHME CORP.Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
-
Publication number: 20190308945Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: ApplicationFiled: October 30, 2017Publication date: October 10, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: BRENDAN M. CROWLEY, IAN M. BELL, ANDREW JOHN HARVEY, WILLIAM D. SHIPE, KENNETH J. LEAVITT, JOHN M. SANDERS, DEODIAL GUY GUIADEEN, LINDA M. SUEN, THOMAS J. GRESHOCK, VANESSA L. RADA
-
Patent number: 10239849Abstract: In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.Type: GrantFiled: November 7, 2016Date of Patent: March 26, 2019Inventors: Michael T. Rudd, Edward J. Brnardic, Yuntae Kim, Robert S. Meissner, Vanessa L. Rada, Shawn J. Stachel, Celina V. Zerbinatti
-
Publication number: 20180327374Abstract: In its many embodiments, the present invention provides substituted cyanopyridine containing compounds of the Formula (I): and acceptable salts thereof, wherein R1, R2, R3, R4, R5, X, Y, Q, and the moiety are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.Type: ApplicationFiled: November 7, 2016Publication date: November 15, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Michael T. Rudd, Edward J. Brnardic, Yuntae Kim, Robert S. Meissner, Vanessa L. Rada, Shawn J. Stachel, Celina V. Zerbinatti
-
Publication number: 20180030007Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammationType: ApplicationFiled: October 9, 2017Publication date: February 1, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
-
Patent number: 9840481Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammationType: GrantFiled: March 20, 2017Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Brendan M. Crowley, Brian T. Campbell, Joseph L. Duffy, Thomas J. Greshock, Deodial G. Guiadeen, Andrew John Harvey, Belinda C. Huff, Kenneth J. Leavitt, Vanessa L. Rada, John M. Sanders, William D. Shipe, Linda M. Suen, Ian M. Bell
-
Patent number: 9815796Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.Type: GrantFiled: December 17, 2014Date of Patent: November 14, 2017Assignees: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhiqiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
-
Publication number: 20170275260Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammationType: ApplicationFiled: March 20, 2017Publication date: September 28, 2017Applicant: MERCK SHARP & DOHME CORP.Inventors: BRENDAN M. CROWLEY, BRIAN T. CAMPBELL, JOSEPH L. DUFFY, THOMAS J. GRESHOCK, DEODIAL G. GUIADEEN, ANDREW JOHN HARVEY, BELINDA C. HUFF, KENNETH J. LEAVITT, VANESSA L. RADA, JOHN M. SANDERS, WILLIAM D. SHIPE, LINDA M. SUEN, IAN M. BELL
-
Publication number: 20170015633Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.Type: ApplicationFiled: December 17, 2014Publication date: January 19, 2017Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhi Qiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
-
Patent number: 9233977Abstract: Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO2—, —O— or NRac—, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.Type: GrantFiled: October 25, 2011Date of Patent: January 12, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: John A. McCauley, Hemaka A. Rajapakse, Thomas J. Greshock, John Sanders, Boyoung Kim, Vanessa L. Rada, Jonathan T. Kern, Heather H. Stevenson, Mark T. Bilodeau